NCT03626948View on ClinicalTrials.gov

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

September 13, 2018

Primary Completion Date

February 4, 2020

Study Completion Date

February 5, 2020

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

SK-1403

Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.

Trial Locations (1)

Unknown

Investigational site (there may be other sites in this country), Tokyo

All Listed Sponsors
lead

Sanwa Kagaku Kenkyusho Co., Ltd.

INDUSTRY

NCT03626948 - SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis | Biotech Hunter | Biotech Hunter